SCHEMBL2789355

SCHEMBL2789355

O=C1CN(Cc2cccc(OCC3CN(c4ccc(C(F)(F)F)cc4)C(=O)O3)c2)C(=O)S1

nearest known ligand 0.60

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 17/20 0.60

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2786197 0.91 GRM2 (0.55) GRM2
SCHEMBL8941939 0.90 GRM2 (0.57) GRM2
SCHEMBL6801533 0.89 GRM2 (0.56) GRM2
SCHEMBL8942117 0.89 GRM2 (0.56) GRM2
SCHEMBL9236212 0.88 GRM2 (0.60) GRM2
SCHEMBL8941844 0.87 GRM2 (0.57) GRM2
SCHEMBL8941850 0.86 GRM2 (0.55) GRM2
SCHEMBL8941876 0.84 GRM2 (0.58) GRM2
SCHEMBL8942024 0.84 GRM2 (0.53) GRM2
SCHEMBL9242572 0.81 GRM2 (0.51) GRM2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6552055-B2 Peroxidsome proliferator activated receptors DANA-FARBER CANCER INSTITUTE 2003-04-22 US claimed
US-20020106796-A1 PAX8-PPARgamma nucleic acid molecules and polypeptides and uses thereof BRIGHAM AND WOMEN'S HOSPITAL, INC., THE 2002-08-08 US claimed
WO-2001052789-A2 PAX8-PPARη NUCLEIC ACID MOLECULES AND POLYPEPTIDES AND USES THEREOF THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2001-07-26 WO claimed
US-20110300129-A1 SYSTEMS AND METHODS FOR ENHANCING VACCINE EFFICACY UNIVERSITY OF ROCHESTER (US) 2011-12-08 US disclosed
WO-2010075037-A1 SYSTEMS AND METHODS FOR ENHANCING VACCINE EFFICACY UNIVERSITY OF ROCHESTER (US) 2010-07-01 WO disclosed
US-7635708-B2 Methods and pharmaceutical compositions for inhibiting tumor cell growth DANA-FARBER CANCER INSTITUTE (US) 2009-12-22 US disclosed
US-20060019910-A1 Methods for treating and preventing insulin resistance and related disorders GREENBERG ANDREW S 2006-01-26 US disclosed
US-20050148536-A1 Methods for treating and preventing insulin resistance and related disorders GREENBERG ANDREW S (US) 2005-07-07 US disclosed
US-6897019-B1 Methods for treating and preventing insulin resistance and related disorders TRUSTEES OF TUFTS COLLEGE 2005-05-24 US disclosed
US-20040171533-A1 Methods and compositions for regulating adiopocytes CURIS, INC. 2004-09-02 US disclosed
EP-1410799-A1 Methods and pharmaceutical compositions for inhibiting tumour cell growth DANA-FARBER CANCER INSTITUTE (US) 2004-04-21 EP disclosed
US-20020006950-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING TUMOR CELL GROWTH DANA-FARBER CANCER INSTITUTE 2002-01-17 US disclosed
WO-2001064238-A2 METHODS AND COMPOSITIONS FOR REGULATING ADIPOCYTES CURIS, INC. (US) 2001-09-07 WO disclosed
WO-2001052789-A2 PAX8-PPARη NUCLEIC ACID MOLECULES AND POLYPEPTIDES AND USES THEREOF THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2001-07-26 WO disclosed
US-6242196-B1 INHIBITING PROLIFERATION OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS-GAMMA RESPONSE HYPERPROLIFERATIVE CELL BY CONTACTING WITH AGONIST AND MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR DANA-FARBER CANCER INSTITUTE 2001-06-05 US disclosed
EP-0948324-A2 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING TUMOUR CELL GROWTH DANA-FARBER CANCER INSTITUTE, INC. (US) 1999-10-13 EP disclosed
WO-1998025598-A9 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING TUMOUR CELL GROWTH 1998-11-26 WO disclosed
WO-1998025598-A2 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING TUMOUR CELL GROWTH DANA-FARBER CANCER INSTITUTE (US) 1998-06-18 WO disclosed
US-5521202-A ANTIDIABETIC AGENTS TAIHO PHARMACEUTICAL CO., LTD. (JP) 1996-05-28 US disclosed
EP-0645387-A1 THIAZOLIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME TAIHO PHARMACEUTICAL CO., LTD. (JP) 1995-03-29 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040171533-A1 Methods and compositions for regulating adiopocytes FABP4, APMAP, ADIPOR1 GRM2 2744/4885
US-20020006950-A1 METHODS AND PHARMACEUTICAL COMPOSITIONS FOR INHIBITING TUMOR CELL GROWTH PPARD, PPARG, PPARA GRM2 2637/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.